SUBSCRIBE
SUBSCRIBE

Scioderm

NEWS
Scioderm was acquired by Amicus Therapeutics in September 2015.
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Deals
Amicus Snaps up Scioderm and its Lead EB Drug in Deal Worth $847 Million
August 31, 2015
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Bio NC
Scioderm Locks In $20 Million Series B
December 18, 2014
 · 
2 min read
IN THE PRESS
Drug Development
Scioderm Initiates Phase 2B Study Of SD-101, A Novel Topical Therapy, For Patients With Epidermolysis Bullosa
January 6, 2014
 · 
5 min read
Drug Development
Scioderm Receives Positive Opinion From European Orphan Medicinal Products Committee For Novel Topical Therapy To Treat Epidermolysis Bullosa
December 17, 2013
 · 
4 min read
Business
Scioderm Appoints Orphan Product Executives To Board Of Directors
December 2, 2013
 · 
3 min read
Bio NC
Scioderm Honored With Partners in Progress Award From DEBRA of America
October 30, 2013
 · 
3 min read
Business
Scioderm’s CEO Dr. Robert Ryan Appointed Member of DebRA Board
October 21, 2013
 · 
3 min read
Drug Development
Novella Clinical Selected by Scioderm to Manage Rare Disease Study
October 15, 2013
 · 
2 min read
BioCapital
Scioderm to Present at Biotechnology Industry Organization (BIO)-Europe 2013 Conference
October 14, 2013
 · 
2 min read
Drug Development
Scioderm’s SD-101 Receives Breakthrough Therapy Designation From FDA for Treatment of Epidermolysis Bullosa
May 6, 2013
 · 
4 min read
Business
Raleigh Startup Scioderm Nets $9 Million
April 30, 2013
 · 
1 min read
Bio NC
Scioderm’s SD-101 Receives Breakthrough Therapy Designation From FDA for Treatment of Epidermolysis Bullosa
April 29, 2013
 · 
4 min read
Load More
AWARDS
  • NextGen Class of 2015